TW200613012A - Sustained-release composition, process for producing the same and use of the same - Google Patents

Sustained-release composition, process for producing the same and use of the same

Info

Publication number
TW200613012A
TW200613012A TW094121375A TW94121375A TW200613012A TW 200613012 A TW200613012 A TW 200613012A TW 094121375 A TW094121375 A TW 094121375A TW 94121375 A TW94121375 A TW 94121375A TW 200613012 A TW200613012 A TW 200613012A
Authority
TW
Taiwan
Prior art keywords
same
sustained
release composition
average molecular
molecular weight
Prior art date
Application number
TW094121375A
Other languages
English (en)
Inventor
Tomomichi Futo
Kei Mukai
Jiichi Arai
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200613012(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of TW200613012A publication Critical patent/TW200613012A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW094121375A 2004-07-02 2005-06-27 Sustained-release composition, process for producing the same and use of the same TW200613012A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004196831 2004-07-02
JP2004267537 2004-09-14
JP2004296635 2004-10-08
JP2005023261 2005-01-31

Publications (1)

Publication Number Publication Date
TW200613012A true TW200613012A (en) 2006-05-01

Family

ID=34971927

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094121375A TW200613012A (en) 2004-07-02 2005-06-27 Sustained-release composition, process for producing the same and use of the same

Country Status (7)

Country Link
US (1) US20080118545A1 (zh)
EP (1) EP1765295B2 (zh)
JP (1) JP5601749B2 (zh)
CA (1) CA2571583C (zh)
ES (1) ES2391460T5 (zh)
TW (1) TW200613012A (zh)
WO (1) WO2006004167A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075762A1 (en) * 2006-12-18 2008-06-26 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
MX2012006441A (es) * 2009-12-22 2012-06-28 Takeda Pharmaceutical Formulacion de liberacion sostenida.
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
US20120270078A1 (en) * 2011-04-08 2012-10-25 Glenn Godden Liquid Battery Formed from Encapsulated Components
WO2014010614A1 (ja) * 2012-07-12 2014-01-16 武田薬品工業株式会社 マイクロカプセル粉末の製造方法
EP3131532A1 (de) 2014-04-16 2017-02-22 Veyx-Pharma GmbH Veterinärpharmazeutische zusammensetzung und deren verwendung
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
EP0190833B1 (en) * 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
DE69129770T2 (de) * 1990-04-13 1998-11-19 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare Polymere, ihre Herstellung und ihre Verwendung
ATE161716T1 (de) * 1992-08-07 1998-01-15 Takeda Chemical Industries Ltd Herstellung von mikrokapseln, die wasserlösliche arzneimittel enthalten
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
JPH08259460A (ja) * 1995-01-23 1996-10-08 Takeda Chem Ind Ltd 徐放性製剤の製造法
TW448055B (en) * 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
CA2192782C (en) † 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
JPH09221420A (ja) * 1995-12-15 1997-08-26 Takeda Chem Ind Ltd ヒドロキサム酸類の徐放性製剤
CA2192773C (en) * 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
US6419961B1 (en) * 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
ES2221019T3 (es) * 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
IL136951A0 (en) * 1998-01-16 2001-06-14 Takeda Chemical Industries Ltd Sustained-release composition, method of its production and use thereof
EP1310517B2 (en) * 2000-08-07 2010-11-17 Wako Pure Chemical Industries, Ltd. Lactic acid polymer and process for producing the same
JP3902518B2 (ja) * 2001-06-29 2007-04-11 武田薬品工業株式会社 徐放性組成物用乳酸−グリコール酸重合体の製造法
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
TW200526267A (en) * 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same
WO2003055470A1 (fr) * 2001-12-26 2003-07-10 Takeda Chemical Industries, Ltd. Nouvelle microsphere et son procede de production
WO2004000363A1 (ja) * 2002-06-25 2003-12-31 Takeda Pharmaceutical Company Limited 徐放性組成物の製造方法
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations

Also Published As

Publication number Publication date
CA2571583A1 (en) 2006-01-12
JP2008505057A (ja) 2008-02-21
JP5601749B2 (ja) 2014-10-08
EP1765295A1 (en) 2007-03-28
EP1765295B1 (en) 2012-09-12
EP1765295B2 (en) 2015-09-09
ES2391460T5 (es) 2015-10-27
WO2006004167A1 (en) 2006-01-12
CA2571583C (en) 2013-04-30
US20080118545A1 (en) 2008-05-22
ES2391460T3 (es) 2012-11-27

Similar Documents

Publication Publication Date Title
TW200613012A (en) Sustained-release composition, process for producing the same and use of the same
CY1111708T1 (el) Συνθεση ελεγχομενης απελευθερωσης και μεθοδος παρασκευης αυτης
Barber et al. Load to failure testing of new meniscal repair devices
MXPA03011440A (es) Composicion de liberacion sostenida y proceso para producirla.
CN102099026B (zh) 含美西特田的治疗组合物
JP2023181359A (ja) 治療剤の制御放出のための埋込み可能なデポー
WO2006059029A3 (fr) Solutions viscoelastiques renfermant du hyaluronate de sodium et de l'hydroxypropylmethyl- cellulose, preparation et utilisations
Odermatt et al. MonoMax suture: A new long‐term absorbable monofilament suture made from poly‐4‐hydroxybutyrate
WO2003007782A3 (en) Biodegradable injectable implants and related methods of manufacture and use
EP2767291A3 (en) Treatment of glycogen storage disease type II
JP2005510521A5 (zh)
EA200601905A1 (ru) Микрокапсулы с замедленным высвобождением, основанные на сополимере лактида и гликолида, включающие полипептид и сахар
WO2003086369A3 (en) Stealthy polymeric biodegradable nanospheres and uses thereof
MY148370A (en) Sustained-release composition and method for producing the same
IL147417A0 (en) Sustained release compositions, methods for producing the same and uses thereof
WO2006107311A3 (en) Biocompatible polymeric vesicles self assembled from triblock copolymers
JPS6413034A (en) Selectively biodegradable polymer blend
JPH02503315A (ja) 機能的に活性な組成物の徐放性を有する固体形態物の製造法
RU2006137349A (ru) Композиции продолжительного действия на основе налтрексона
PL363007A1 (en) Pharmaceutical form of administration for peptides, methods for its production and use
MXPA02012064A (es) Complejos de farmaco macromoleculares y composiciones que los contienen.
AR033918A1 (es) Composicion para acelerar la soldadura de una fractura osea
AR034044A1 (es) Composicion para el tratamiento reconstituyente en enfermedades de cartilago
WO2004037311A3 (en) Device and methods for sequential, regional delivery of multiple cytotoxic agents
ATE197310T1 (de) Polymere mit kontrolliertem physikalischen zustand und bioerodierbarkeit